• Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732).
  

PubMed=8027550; DOI=10.4049/jimmunol.153.3.1225
Marincola F.M., Shamamian P., Alexander R.B., Gnarra J.R., Turetskaya R.L., Nedospasov S.A., Simonis T.B., Taubenberger J.K., Yannelli J.R., Mixon A., Restifo N.P., Herlyn M., Rosenberg S.A.
Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.
J. Immunol. 153:1225-1237(1994)

PubMed=8081556; DOI=10.1097/00002371-199407000-00002; PMCID=PMC2561308
Marincola F.M., Shamamian P., Simonis T.B., Abati A.D., Hackett J.A., O'Dea T., Fetsch P.A., Yannelli J.R., Restifo N.P., Mule J.J., Rosenberg S.A.
Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.
J. Immunother. Emphasis Tumor Immunol. 16:13-23(1994)

PubMed=8537970; DOI=10.1093/jnci/88.2.100; PMCID=PMC2248456
Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J.K., Yannelli J.R., Rosenberg S.A.
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
J. Natl. Cancer Inst. 88:100-108(1996)

PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C., Fountain J.W.
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998)

PubMed=9670966; DOI=10.4049/jimmunol.161.2.877
Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N., Panelli M.C., Parker K.K., Marincola F.M.
Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy.
J. Immunol. 161:877-889(1998)

PubMed=10048982; DOI=10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A; PMCID=PMC2072935
Cormier J.N., Panelli M.C., Hackett J.A., Bettinotti M.P., Mixon A., Wunderlich J.R., Parker L.L., Restifo N.P., Ferrone S., Marincola F.M.
Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model.
Int. J. Cancer 80:781-790(1999)

PubMed=10754339; DOI=10.4049/jimmunol.164.8.4382
Panelli M.C., Bettinotti M.P., Lally K., Ohnmacht G.A., Li Y., Robbins P.F., Riker A., Rosenberg S.A., Marincola F.M.
A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12.
J. Immunol. 164:4382-4392(2000)

PubMed=15467732; DOI=10.1038/sj.onc.1208152
Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J., Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Oncogene 23:8796-8804(2004)

PubMed=16470173; DOI=10.1038/sj.jid.5700193
Wang E., Voiculescu S., Le Poole I.C., El-Gamil M., Li X., Sabatino M., Robbins P.F., Nickoloff B.J., Marincola F.M.
Clonal persistence and evolution during a decade of recurrent melanoma.
J. Invest. Dermatol. 126:1372-1377(2006)

PubMed=18172304; DOI=10.1158/0008-5472.CAN-07-1939
Sabatino M., Zhao Y.-D., Voiculescu S., Monaco A., Robbins P.F., Karai L., Nickoloff B.J., Maio M., Selleri S., Marincola F.M., Wang E.
Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis.
Cancer Res. 68:122-131(2008)

PubMed=25502142; DOI=10.1038/ncomms6712; PMCID=PMC4428333
Muller J., Krijgsman O., Tsoi J., Robert L., Hugo W., Song C., Kong X.-J., Possik P.A., Cornelissen-Steijger P.D.M., Geukes Foppen M.H., Kemper K., Goding C.R., McDermott U., Blank C., Haanen J.B.A.G., Graeber T.G., Ribas A., Lo R.S., Peeper D.S.
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
Nat. Commun. 5:5712.1-5712.15(2014)

PubMed=25538140; DOI=10.15252/msb.20145450; PMCID=PMC4300494
Smit M.A., Maddalo G., Greig K., Raaijmakers L.M., Possik P.A., van Breukelen B., Cappadona S., Heck A.J.R., Altelaar A.F.M., Peeper D.S.
ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma.
Mol. Syst. Biol. 10:772-772(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)